Testosterone Enanthate: EMA vs FDA Regulatory Approach

How the FDA Originally Approved Testosterone Enanthate

The FDA approved testosterone enanthate in 1953, making it one of the earliest androgen products on the US market. The approved indication was, and remains, hypogonadism in males whose bodies do not produce enough testosterone. Delatestryl (Endo Pharmaceuticals) is the most widely cited branded product, though multiple generic manufacturers now hold abbreviated NDA approvals.

The NDA Pathway and Indication Scope

Under 21 CFR Part 310, the original NDA covered primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) in adult males. The FDA has not approved testosterone enanthate for age-related low testosterone in otherwise healthy older men. The T-Trials, published in the New England Journal of Medicine in 2016 (N=788), showed statistically significant improvements in sexual function and bone density in men 65 and older given testosterone gel, but the trial also found a higher rate of coronary artery calcium progression in the treated group compared with placebo [1]. That cardiovascular signal reinforced the FDA's position against expanding the hypogonadism indication to include age-related decline.

Controlled Substance Classification

Since 1990, testosterone enanthate has been a Schedule III controlled substance under the Anabolic Steroid Control Act (21 USC 812). Schedule III status means prescribers face DEA registration requirements, record-keeping obligations, and a 30-day non-refillable prescription limit in most states. Pharmacies must store testosterone enanthate in a locked cabinet with Schedule III inventory logs. This is a regulatory layer that the EMA framework does not replicate in the same centralized fashion.

FDA Labeling: Current Prescribing Information

The FDA-approved prescribing information for testosterone enanthate carries a boxed warning at the top of the document. The warning text reads, per the FDA-approved label: "Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel." [2] A separate section of the label adds the abuse and dependence boxed warning, noting that testosterone enanthate is a Schedule III controlled substance with potential for abuse and dependence. The current label lists the following contraindications:

• Breast cancer in males
• Known or suspected prostate carcinoma
• Pregnancy (Category X)
• Serious cardiac, hepatic, or renal disease

The label also mandates a REMS (Risk Evaluation and Mitigation Strategy) for testosterone products broadly, though the testosterone REMS program focuses on preventing inappropriate pediatric and female exposure rather than on the drug's cardiovascular risk profile.

How the EMA Regulates Testosterone Enanthate

Testosterone enanthate does not have a centralized European Public Assessment Report (EPAR) through the EMA's centralized procedure. The EMA's centralized procedure is mandatory only for certain categories of medicines, including biologics and orphan drugs, and is optional for other products. Testosterone enanthate, a small-molecule synthetic androgen approved decades before the EMA's centralized procedure existed, is regulated through national competent authorities (NCAs) in each EU member state.

National Competent Authorities and Mutual Recognition

In Germany, the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) holds the national marketing authorization for products like Testoviron Depot (Bayer). In the Netherlands, the Medicines Evaluation Board (CBG-MEB) oversees domestic approvals. The mutual recognition procedure (MRP) and the decentralized procedure (DCP) allow a manufacturer to use one NCA's positive assessment as the basis for authorization across other member states. This means labeling can vary slightly between EU countries, a structural difference from the single FDA-approved label that governs all US prescribing.

EMA Pharmacovigilance: EudraVigilance

The EMA's pharmacovigilance arm relies on EudraVigilance, the European database of suspected adverse drug reactions. Marketers of testosterone enanthate in the EU must submit Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) to their respective NCA. The EMA coordinates signal detection across member states through the Pharmacovigilance Risk Assessment Committee (PRAC). As of 2024, PRAC has reviewed androgenic anabolic steroids as a class and confirmed that cardiovascular risk warnings should appear on all member-state labels [3].

EU Controlled Substance Status

Across most EU member states, testosterone enanthate is a prescription-only medicine and is listed under national controlled drug schedules. In the United Kingdom (pre-Brexit regulatory period governed by MHRA, now operating independently), testosterone enanthate was a Class C controlled drug under the Misuse of Drugs Act 1971. Germany classifies it under the Betäubungsmittelgesetz (BtMG). These country-by-country classifications create compliance complexity for telehealth platforms operating across jurisdictions.

Key Differences in FDA vs EMA Label Language

The most clinically significant divergence between the FDA and EMA approaches is in the specificity of the cardiovascular risk language. Both frameworks require a cardiovascular warning, but the wording and the evidentiary threshold for updating that language differ.

Cardiovascular Risk Warnings

The FDA issued a Drug Safety Communication in 2015 requiring all approved testosterone products to carry a warning about the potential for increased risk of heart attack and stroke [4]. This communication followed a review of published studies, including a JAMA Internal Medicine analysis (N=8,709) by Finkle et al. That found a 36% increase in non-fatal myocardial infarction in the 90 days following testosterone prescription initiation [5]. The FDA communication stopped short of concluding causality but required prescribers to discuss cardiovascular risk with patients before initiating therapy.

The EMA's PRAC completed a parallel review and issued its own conclusion in 2014, requiring EU labels to state that testosterone medicines should be used with caution in patients with pre-existing cardiovascular disease. The EMA's language was slightly less directive than the FDA's and did not specify a 90-day elevated risk window. The EMA also did not require a boxed warning; it required a bolded warning within the Special Warnings and Precautions section of the summary of product characteristics (SmPC).

Polycythemia and Venous Thromboembolism

Both agencies flag polycythemia (elevated hematocrit) as a dose-dependent risk. The FDA label recommends checking hematocrit before initiating therapy, at 3 to 6 months, and then annually. A hematocrit above 54% should prompt dose reduction or therapy discontinuation according to the FDA-approved prescribing information. The EMA SmPC in most member states carries identical threshold guidance, derived from the same pharmacological literature.

Venous thromboembolism (VTE) risk added explicit label language in both jurisdictions following the EMA's 2013 to 2014 PRAC review. The FDA updated its testosterone label to include VTE as a recognized risk in 2014 [4]. Both agencies cite the prothrombotic effect of elevated hemoglobin and hematocrit, as well as estradiol conversion through aromatization, as the mechanistic basis for the VTE signal.

Hepatotoxicity Language

The FDA label for testosterone enanthate notes peliosis hepatis, hepatic neoplasms, and cholestatic hepatitis as risks, primarily associated with long-term high-dose androgen use. The EMA SmPC language is structurally similar. Neither agency considers injectable testosterone enanthate as high-risk for hepatotoxicity as 17-alpha-alkylated oral androgens, because enanthate is not C-17 alkylated. The warning exists in both labels largely for class labeling consistency.

Post-Market Surveillance: FDA Sentinel vs EudraVigilance

The FDA and EMA use structurally different post-market surveillance architectures, and those differences affect how safety signals for testosterone enanthate are detected and acted upon.

FDA Sentinel System

The FDA Sentinel System is an active surveillance network that links claims and electronic health record data from more than 100 million patients across US health insurers and health systems [6]. For testosterone enanthate specifically, Sentinel allows the FDA to run near-real-time queries looking for disproportionate rates of myocardial infarction, stroke, pulmonary embolism, and erythrocytosis in testosterone-treated patients compared with matched controls. This is a prospective, population-level tool. Its outputs have informed FDA Drug Safety Communications and labeling updates faster than passive MedWatch reporting alone.

Passive surveillance through MedWatch still operates in parallel. Prescribers, pharmacists, and patients can submit voluntary adverse event reports, which feed into the FDA Adverse Event Reporting System (FAERS). Between 2004 and 2023, FAERS accumulated over 14,000 adverse event reports linked to testosterone products broadly, with cardiovascular events and psychiatric effects (aggression, dependence) among the most frequently reported categories [7].

EudraVigilance and PRAC Signal Detection

EudraVigilance aggregates spontaneous adverse reaction reports from EU member states, non-EU countries in the European Economic Area, and marketing authorization holders. The PRAC reviews these signals quarterly. A signal is formally triggered when the reporting odds ratio for a drug-event pair crosses a predefined threshold, typically using a disproportionality analysis algorithm comparable to the FDA's empirical Bayes geometric mean method.

The EMA's system is less integrated with electronic health record data than FDA Sentinel. The PRAC relies more heavily on published literature, PSURs from manufacturers, and spontaneous reports. For testosterone enanthate, this means that EU signal detection is somewhat slower than US detection, and that the EMA's label updates have generally followed FDA communications rather than preceded them. The 2014 VTE warning is one example: the FDA issued its communication in October 2014, and the EMA's PRAC recommendation followed in November 2014 [3][4].

Off-Label Use: Regulatory Positions on TRT in Women and Fertility Applications

Neither the FDA nor the EMA has approved testosterone enanthate for use in women. The Endocrine Society's 2019 Clinical Practice Guideline on testosterone therapy in women states: "We recommend against the routine prescription of testosterone to treat infertility, cardiovascular or metabolic disease, cognitive function, general well-being, or musculoskeletal health in women." [8] That guideline also notes that no testosterone formulation is currently approved for women in the United States or in most EU member states.

Use in Male Infertility Protocols

Testosterone enanthate is sometimes used off-label in combination protocols for male fertility, though this is paradoxical given that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis and reduces intratesticular testosterone and sperm production. Its use in male contraceptive trials, including the WHO's 1990 study (N=271) showing 98.6% efficacy in achieving azoospermia or severe oligospermia [9], has not led to regulatory approval in either jurisdiction for this indication.

Telehealth Platform Compliance Obligations

For US-based telehealth platforms prescribing testosterone enanthate, the regulatory requirements include:

• Prescriber DEA registration (Schedule III)
• State-specific prescribing rules for controlled substances via telehealth
• Compliance with the FDA's testosterone REMS program
• Documentation of confirmed hypogonadism diagnosis (two morning serum testosterone measurements below the laboratory reference range)
• Baseline and follow-up hematocrit monitoring per label

For EU-based telehealth platforms, the obligations vary by country. In Germany, for instance, the Telemedizin framework requires a confirmed diagnosis and periodic in-person or video follow-up; prescribing a BtMG-listed substance purely via asynchronous consultation is not permitted.

What the Approval History Means for Clinicians Today

The 1953 FDA approval date matters because it predates modern randomized controlled trial requirements. Testosterone enanthate reached the market under the older NDA standard that did not mandate large Phase III efficacy trials. The T-Trials (NEJM, 2016) were the first large, placebo-controlled RCT to rigorously evaluate testosterone therapy in older men with low testosterone, and their mixed results have had a direct effect on how both the FDA and EMA view label expansion requests [1].

The 2015 FDA Advisory Committee Meeting

In September 2014, the FDA convened an advisory committee to evaluate whether testosterone products should carry stronger cardiovascular warnings. The committee voted 20 to 1 in favor of requiring a cardiovascular risk warning on all testosterone product labels [4]. The resulting 2015 label update specified that prescribers should evaluate cardiovascular risk factors before initiating therapy and should re-evaluate patients who experience major adverse cardiovascular events while on treatment.

Current FDA-Approved Dosing Range

The FDA-approved dosing range for testosterone enanthate in adult males with hypogonadism is 50 to 400 mg administered intramuscularly every 2 to 4 weeks. Most clinical practice guidelines, including those from the American Urological Association and the Endocrine Society, favor more frequent dosing (e.g., 100 mg weekly or 200 mg every 2 weeks) to reduce peak-to-trough fluctuation in serum testosterone and the associated symptom variability. The FDA label does not specify weekly dosing; that practice pattern is driven by clinical convention rather than labeled guidance.

Generic Manufacturers and Bioequivalence Standards

The FDA requires generic testosterone enanthate products to demonstrate bioequivalence to the reference listed drug under 21 CFR Part 320. Bioequivalence testing for injectable oil-based products involves demonstrating that the 90% confidence interval for the ratio of AUC and Cmax falls within 80 to 125% of the reference product. Multiple manufacturers, including Hikma Pharmaceuticals and Pfizer (via its generics division), hold ANDA approvals for testosterone enanthate 200 mg/mL in sesame oil. The EMA requires equivalent bioequivalence data through the relevant NCA, using guidelines consistent with EMA/CHMP/EWP/QWP/1401/98.

Safety Profile: What Both Agencies Agree On

Despite the structural differences between the two regulatory systems, the FDA and EMA have converged on a broadly consistent safety profile for testosterone enanthate. This convergence reflects the shared evidence base, primarily the same published clinical literature and the same manufacturer-submitted pharmacovigilance data.

Shared Label Warnings Across Both Jurisdictions

Both the FDA label and EMA-aligned SmPCs require warnings for the following:

• Cardiovascular events (myocardial infarction, stroke) based on the 2014 to 2015 safety reviews
• Polycythemia with hematocrit monitoring thresholds
• VTE, including deep vein thrombosis and pulmonary embolism
• Sleep apnea exacerbation
• Hepatic effects (peliosis hepatis, cholestatic jaundice, hepatocellular carcinoma with prolonged high-dose use)
• Edema with or without congestive heart failure in patients with preexisting cardiac or renal disease
• Gynecomastia
• Infertility due to HPG axis suppression
• Potential virilization in female sexual partners or children through secondary exposure

Where the Evidence Is Still Incomplete

The cardiovascular risk data for testosterone enanthate remain contested. The T-Trials showed an increase in coronary artery calcium score of 41 Agatston units in the testosterone group versus 26 units in placebo at 12 months (P<0.001) [1]. A separate analysis from the same trial found no significant difference in carotid intima-media thickness. The FDA's 2015 label update acknowledged this uncertainty. The ongoing TRAVERSE trial (NCT03518034, N=5,204), evaluating testosterone's cardiovascular safety in men with hypogonadism and elevated cardiovascular risk, was published in 2023 and showed that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events, with a hazard ratio of 0.96 (96.05% CI, 0.78 to 1.17) [10]. TRAVERSE data may prompt future FDA label revisions.